Royal Bank of Canada’s Faeth Therapeutics FTH Stock Holding History

Royal Bank of Canada’s Portfolio FTH Stock Details FTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-12	Closed	–	–	7391
2024 Q2	$0	Buy	12 +9	+300%	+$187	﹤0.01%	7495
2024 Q1	$0	Sell	3 -24	-89%	-$414	﹤0.01%	7544
2023 Q4	$0	Buy	27 +15	+125%	+$205	﹤0.01%	7542
2023 Q3	$0	Sell	12 -12	-50%	-$258	﹤0.01%	7540
2023 Q2	$1K	Buy	24 +21	+700%	+$615	﹤0.01%	7074
2023 Q1	$0	Buy	+3	New	+$89	﹤0.01%	7440
2022 Q4	–	Sell	-4	Closed	-$118	–	7676
2022 Q3	$0	Buy	+4	New	+$157	﹤0.01%	7824
2022 Q2	–	Sell	-64	Closed	-$3K	–	7690
2022 Q1	$3K	Sell	64 -153	-71%	-$12.2K	﹤0.01%	7400
2021 Q4	$26K	Buy	217 +96	+79%	+$14.3K	﹤0.01%	6683
2021 Q3	$25K	Buy	121 +87	+256%	+$15.8K	﹤0.01%	6582
2021 Q2	$7K	Sell	34 -3	-8%	-$741	﹤0.01%	6985
2021 Q1	$11K	Buy	+37	New	+$12.4K	﹤0.01%	6772

Other funds holding FTH

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.29% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

National Bank of Canada Montreal, Quebec, Canada $112B AUM 31.26% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Royal Bank of Canada's FTH Position: Q3 2024 in Review

Royal Bank of Canada sold out of Faeth Therapeutics (FTH) in Q3 2024, closing a stake of 12 shares.

Royal Bank of Canada first reported a position in FTH in Q1 2021 and held it in 12 quarters. The position peaked at $26K in Q4 2021. 19 funds tracked by Wall St. Rank hold FTH as of Q3 2024.

Royal Bank of Canada reported no remaining Faeth Therapeutics position as of Q3 2024 after selling out during the quarter.
Royal Bank of Canada sold 12 Faeth Therapeutics shares in Q3 2024.
Royal Bank of Canada first reported a position in Faeth Therapeutics in Q1 2021 and held it in 12 quarters.
Royal Bank of Canada's Faeth Therapeutics position peaked at $26K in Q4 2021.
19 funds tracked by Wall St. Rank held Faeth Therapeutics as of Q3 2024.

Based on Royal Bank of Canada's 13F filing for Q3 2024, filed 14 Nov 2024.